Investor Update Conference Call Set for March 7
NAPA, Calif., March 4 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced it has entered into a contractual dispute resolution process with Triax Aesthetics LLC, the privately-held specialty pharmaceuticals marketer which Senetek licensed in August 2007 to sell a line of skincare products featuring Senetek's new Pyratine-6(TM) active ingredient to dermatologists and other physicians who prescribe or dispense products and to chain drug stores for sale at the pharmacist's counter.
Senetek also announced that it will conduct a teleconference for investors on Friday, March 7, 2008 at 9:00 a.m. Pacific time, 12:00 p.m. Eastern time, at which Senetek management will give an update on the business including the appointment of two veteran sales and marketing executives and a Vice President of Communications. The domestic dial-in number will be 877-593-8638 and the international dial-in number will be 706-634-9240, conference ID 37979186. Replay of the conference call will be available until March 14, 2008, domestic replay dial-in 800-642-1687, international replay dial-in 706-645-9291, replay conference ID 37979186.
About Senetek PLC
Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company
engaged in the development of breakthrough technologies that target the
science of healthy aging. The Company's extensive research collaborations
have resulted in a strong pipeline of patented compounds and products with
broad therapeutic applications and a leading presence in dermatology.
Senetek collaborates with established specialty pharmaceutical companies in
the final development and marketing of its proprietary products, most
recently resulting in the development of the best-selling anti-aging
product sold in the North American physician marke
|SOURCE Senetek PLC|
Copyright©2008 PR Newswire.
All rights reserved